Veru Inc. to Showcase Key Findings at ObesityWeek 2025
Veru Inc. (NASDAQ: VERU), a leading biopharmaceutical company, is making significant strides in the field of cardiometabolic and inflammatory diseases. The company has announced the presentation of two important abstracts at ObesityWeek 2025, which takes place in the first week of November. This event serves as a prominent platform for industry experts to discuss advancements in obesity treatment and research.
Details of the Presentations
One of the highlights of the conference is a poster presentation titled "Enobosarm Reduced Body Weight and Fat Regain and Preserved Lean Mass After Discontinuing Semaglutide". This poster will be presented by Dr. Steven B. Heymsfield, a Professor and Director of the Body Composition-Metabolism Laboratory. Attendees can find this presentation on November 4th during the 7:30 pm to 8:30 pm session.
Additionally, Dr. Mitchell Steiner, who is the Chairman, President, and CEO of Veru Inc., will deliver an oral presentation entitled "Enobosarm in Combination With GLP-1RA is Selective for Fat Loss While Preserving Lean and Function". This session is scheduled for November 7th, from 8:00 am to 8:15 am. Both presentations underscore Veru's commitment to advancing therapeutic options for individuals dealing with obesity.
Enobosarm and Its Role in Obesity Treatment
Enobosarm is a selective androgen receptor modulator (SARM) designed to facilitate weight reduction while maintaining lean body mass. This innovative approach aims to enhance the efficacy of existing GLP-1 receptor agonist (RA) treatments, such as semaglutide. By improving tissue selectivity for fat loss, enobosarm provides a promising avenue for achieving better body composition outcomes and enhanced physical function.
Veru's recent Phase 2b QUALITY clinical study focused on evaluating the safety and efficacy of enobosarm. This randomized, double-blind study involved 168 older adults (aged 60 and above) who were using semaglutide for weight reduction. Initial findings demonstrated that enobosarm, when combined with semaglutide, helped preserve muscle mass during the weight loss phase, which leads to more sustainable weight management in the longer term.
Looking Ahead: PLATEAU Clinical Study
Building on these promising results, Veru is preparing to launch a Phase 2b PLATEAU clinical study. The objective of this upcoming study is to evaluate the effectiveness of enobosarm in supporting older and younger patients initiating GLP-1 RA treatment. Conducted over 72 weeks, this study will assess total body weight changes, physical function, and safety across a diverse patient demographic. A crucial aspect of the study will include an interim analysis at 36 weeks to monitor changes in lean body mass and fat mass.
Enobosarm represents a potential breakthrough in addressing the weight loss plateau often experienced by patients on GLP-1 RA treatments. Through its unique mechanism, enobosarm aims to aid in achieving clinically significant weight reduction while safeguarding muscle mass and enhancing physical capabilities.
About Veru Inc.
Veru Inc. is dedicated to developing pioneering medicines that target cardiometabolic and inflammatory conditions. The company’s innovative drug development portfolio includes two late-stage novel small molecules: enobosarm and sabizabulin. Sabizabulin is another promising candidate being developed to address inflammation associated with atherosclerotic cardiovascular disease.
With ongoing efforts and strategic clinical studies, Veru seeks to provide effective solutions for obesity-related challenges and improve quality of life for patients affected by these conditions.
Frequently Asked Questions
What are the main presentations Veru is showcasing at ObesityWeek 2025?
Veru will present a poster on enobosarm’s effects on body weight and an oral presentation on its role with GLP-1RA treatments.
Who are the presenters for Veru's abstracts?
Dr. Steven B. Heymsfield will present the poster, while Dr. Mitchell Steiner will deliver the oral presentation.
What is enobosarm?
Enobosarm is a selective androgen receptor modulator designed to enhance fat loss while preserving lean mass during weight management treatments.
When is the planned Phase 2b PLATEAU clinical study expected to begin?
The Phase 2b PLATEAU clinical study is anticipated to start in the first quarter of 2026.
What is the goal of the PLATEAU clinical study?
The study aims to evaluate enobosarm’s ability to support weight loss while preserving muscle mass in patients beginning GLP-1 RA treatment.
